TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Nov 30, 2022 09:31 JST
Source:
Biogen
Eleven Experts from Leading Medical Institutions and Eight Experts from Eisai Publish Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease in the New England Journal of Medicine
TOKYO, Nov 30, 2022 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the results from Eisai's large global Phase 3 confirmatory Clarity AD clinical study of lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain, were published in the New England Journal of Medicine, one of the world's most prestigious peer-reviewed medical journals. For the details of the paper, please refer to: www.nejm.org/doi/full/10.1056/NEJMoa2212948.
The rapid publication of the Clarity AD study results demonstrates Eisai's strong commitment to trust and transparency based on Eisai's human health care mission. Eisai and Biogen remain committed to disclosing data and information on lecanemab. If approved, we will work to bring the drug expeditiously to people living with early AD and their families.
Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.
This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such an investigational agent will successfully gain health authority approval.
For more information, visit www.eisai.com/news/2022/pdf/enews202284pdf.pdf.
Source: Biogen
Sectors: BioTech
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
May 21 2026 23:23 JST
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
April 21 2026 19:52 JST
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy
March 27 2026 19:14 JST
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
March 27 2026 17:19 JST
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
March 23 2026 10:19 JST
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
March 19 2026 09:54 JST
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
March 17 2026 18:49 JST
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration
March 12 2026 16:21 JST
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
March 11 2026 11:07 JST
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
March 02 2026 08:49 JST
More Press release >>
Latest Press Release
Mazda Advances Toward Commercialization of Onboard CO2 Capture System
Jun 09, 2026 00:03 JST
Collaboration Between OCTARVIA Programs and MiPoLin(R)
Jun 08, 2026 23:34 JST
Hitachi joins Anthropic's "Project Glasswing" an AI-powered security program
Jun 08, 2026 23:04 JST
Hitachi and Intel announce strategic collaboration to accelerate AI transformation across key industries
Jun 08, 2026 22:38 JST
Island States Ocean Summit Concludes Launch of the "OCEAN STATES INITIATIVE"
Jun 08, 2026 14:00 JST
Operations Started for the Nagaoka Methanation Demonstration Utilizing the CO2NNEX(R) Digital Platform for Transfer and Management of e-Methane Clean Gas Certificates
Jun 04, 2026 23:49 JST
Fujitsu and Daiichi Life Group Launch Joint Research to Advance Asset Management with Quantum Technology
Jun 04, 2026 23:17 JST
"Making Children and Adults Smile:" Honda Launches the SMILE RIDER PROJECT
Jun 04, 2026 22:46 JST
GR Premiers GRMN Corolla
Jun 04, 2026 22:05 JST
Island States Ocean Summit Opens in Tokyo
Jun 04, 2026 12:00 JST
Mazda and Nippon Express Launch Demonstration Trial Using Biodiesel Fuel
Jun 04, 2026 00:26 JST
NEC Wins at the Newsweek AI Impact Awards 2026
Jun 04, 2026 00:09 JST
Mitsubishi Heavy Industries and Preferred Networks Form Business Alliance to Jointly Develop Japan-Made AI Technologies for Mission-Critical Applications
Jun 03, 2026 23:51 JST
JAL Engineering and Mitsubishi Heavy Industries Establish Joint Venture "Aero Breath" for Aircraft Aftermarket Business
Jun 03, 2026 23:27 JST
MHI Receives Waste Treatment Technology Verification Report from JESC for Its Biomass High-Efficiency Recovery and Recycling System AdBio
Jun 03, 2026 23:02 JST
DUNLOP and Fujitsu Reduce Tire Structural Analysis Time by Approximately 90% Using AI
Jun 03, 2026 22:31 JST
153 elevators and escalators delivered for the New Taipei Metro Sanying Line in Taiwan
Jun 03, 2026 11:00 JST
Fujitsu Launches AI-Powered Service to Analyze Non-Financial Disclosure and Enhance Corporate Value
May 29, 2026 22:11 JST
Sigenergy Unveils SigenAgent, the First All-Domain AI Agent for the Renewable Energy Industry
May 29, 2026 21:47 JST
Wheelchair Racer Catherine Debrunner Breaks Her Own World Record, Sets New Mark in the 200 Meters (T53) at the World Para Athletics Grand Prix (Switzerland)
May 27, 2026 22:45 JST
More Latest Release >>